EA201200994A1 - ANTIBODIES TO CD37 - Google Patents

ANTIBODIES TO CD37

Info

Publication number
EA201200994A1
EA201200994A1 EA201200994A EA201200994A EA201200994A1 EA 201200994 A1 EA201200994 A1 EA 201200994A1 EA 201200994 A EA201200994 A EA 201200994A EA 201200994 A EA201200994 A EA 201200994A EA 201200994 A1 EA201200994 A1 EA 201200994A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
pathology
autoimmune
involved
cells
Prior art date
Application number
EA201200994A
Other languages
Russian (ru)
Inventor
Карл-Хайнц Хайдер
Эрик Боргес
Элинборг Остерманн
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200994(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201200994A1 publication Critical patent/EA201200994A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В заявке описаны химерные и гуманизированные антитела к CD37 и содержащие их фармацевтические композиции, предназначенные для лечения В-клеточных злокачественных заболеваний и аутоиммунных и воспалительных болезней, в патологии которых участвуют В-клетки.The application describes chimeric and humanized antibodies to CD37 and pharmaceutical compositions containing them, intended for the treatment of B-cell malignant diseases and autoimmune and inflammatory diseases, in the pathology of which B-cells are involved.

EA201200994A 2007-08-09 2008-08-08 ANTIBODIES TO CD37 EA201200994A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114128 2007-08-09

Publications (1)

Publication Number Publication Date
EA201200994A1 true EA201200994A1 (en) 2012-12-28

Family

ID=38925567

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201200994A EA201200994A1 (en) 2007-08-09 2008-08-08 ANTIBODIES TO CD37
EA201000274A EA027499B1 (en) 2007-08-09 2008-08-08 Anti cd37 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201000274A EA027499B1 (en) 2007-08-09 2008-08-08 Anti cd37 antibodies

Country Status (37)

Country Link
US (7) US20100189722A1 (en)
EP (3) EP2562187B1 (en)
JP (3) JP5325216B2 (en)
KR (1) KR101593403B1 (en)
CN (4) CN102276724A (en)
AR (2) AR071242A1 (en)
AU (1) AU2008285590B2 (en)
BR (2) BRPI0823331A2 (en)
CA (1) CA2693464C (en)
CL (3) CL2008002349A1 (en)
CO (1) CO6251371A2 (en)
CY (1) CY1117101T1 (en)
DK (1) DK2178915T3 (en)
EA (2) EA201200994A1 (en)
EC (2) ECSP109946A (en)
ES (1) ES2555202T3 (en)
HK (1) HK1220708A1 (en)
HR (1) HRP20160009T1 (en)
HU (1) HUE026221T2 (en)
IL (1) IL202645A (en)
MA (1) MA32665B1 (en)
ME (1) ME02300B (en)
MY (1) MY157555A (en)
NZ (2) NZ600022A (en)
PE (3) PE20120259A1 (en)
PH (1) PH12014501812B1 (en)
PL (1) PL2178915T3 (en)
PT (1) PT2178915E (en)
RS (1) RS54359B1 (en)
SG (1) SG190657A1 (en)
SI (1) SI2178915T1 (en)
TN (1) TN2010000068A1 (en)
TW (2) TW201512220A (en)
UA (2) UA105445C2 (en)
UY (1) UY31275A1 (en)
WO (1) WO2009019312A2 (en)
ZA (1) ZA200908758B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
PE20120259A1 (en) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2011076922A1 (en) * 2009-12-23 2011-06-30 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
NO331080B1 (en) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmune conjugates, pharmaceutical compositions and kits comprising the same and their use
SG10202001677QA (en) * 2010-03-12 2020-04-29 Debiopharm International S A Cd37-binding molecules and immunoconjugates thereof
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
US20120107317A1 (en) * 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
CN105999293B (en) 2011-04-01 2019-07-23 德彪发姆国际有限公司 CD37 binding molecule and its immunoconjugates
CN107903325B (en) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
CN104114192A (en) * 2011-12-13 2014-10-22 诺帝克纳诺维科特公司 Chimeric therapeutic anti-CD37 antibodie HH1
SG11201405766SA (en) * 2012-03-30 2014-10-30 Immunogen Inc Methods for increasing efficacy of cd37-based therapy
EP2841099A1 (en) * 2012-04-26 2015-03-04 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with bendamustine
JP2015517511A (en) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combined use of CD37 antibody and ICE (ifosfamide, carboplatin, etoposide)
US20130309224A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab
WO2013177367A2 (en) * 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
WO2014198330A1 (en) * 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with chlorambucil
JP6510518B2 (en) 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Antibody-drug conjugate (ADC) that binds to the CD37 protein
US9291244B2 (en) 2014-01-17 2016-03-22 Ford Global Technologies, Llc Nine speed automatic transmission
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
SG10202108116SA (en) 2015-06-08 2021-08-30 Debiopharm International S A Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
PL3124976T3 (en) 2015-07-28 2019-02-28 F. Hoffmann-La Roche Ag Improved bacterial endotoxin test for the determination of endotoxins
WO2017040247A1 (en) 2015-08-28 2017-03-09 Immunogen, Inc. Antibodies and assays for detection of cd37
AU2016326449B2 (en) 2015-09-21 2024-10-31 Aptevo Research And Development Llc CD3 binding polypeptides
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
EP4289484A3 (en) 2016-12-07 2024-03-06 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
JP7254710B2 (en) 2017-03-16 2023-04-10 ザ ジェネラル ホスピタル コーポレイション Chimeric Antigen Receptors Targeting CD37
AU2018242227A1 (en) * 2017-03-31 2019-10-17 Genmab Holding B.V. Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
US11696572B2 (en) * 2017-06-27 2023-07-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ASGR1 locus
JP7513530B2 (en) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． Anti-CD37 and Anti-CD20 Antibodies, Compositions, and Methods of Use Thereof
WO2019246546A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
JPWO2020004337A1 (en) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 CD37 specific chimeric antigen receptor
BR112021006055A2 (en) 2018-10-04 2021-07-20 Genmab Holding B.V. pharmaceutical composition, use of the pharmaceutical composition, and, methods for inducing cell death or for inhibiting the growth and/or proliferation of a tumor cell and for treating an individual.
EP4021579A1 (en) * 2019-08-30 2022-07-06 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
KR20240099178A (en) * 2021-10-18 2024-06-28 다이이찌 산쿄 가부시키가이샤 Anti-CD37 antibody-drug conjugate
WO2024118480A1 (en) * 2022-11-28 2024-06-06 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
JPH03504605A (en) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド Lyophilized formulation of antibody production
EP0967277A3 (en) * 1988-09-06 2003-10-15 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0393438B1 (en) 1989-04-21 2005-02-16 Amgen Inc. TNF-receptor, TNF-binding protein and DNA coding therefor
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2193136T3 (en) 1991-08-14 2003-11-01 Genentech Inc IMMUNOGLUBINE VARIANTS FOR SPECIFIC RECEIVERS OF FC EPSILON.
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
RU2139092C1 (en) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Use of antibody fragment in therapy
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP4046354B2 (en) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Immunoglobulin-like domain with increased half-life
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
DE19911329A1 (en) 1998-03-27 2000-09-21 Benes Ivan Friedrich Radioimmunoconjugate which can be used in human therapy and process for its preparation
DE69937291T2 (en) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco ANTIBODY VARIANTS AND FRAGMENTS THEREOF
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PT1242401E (en) 1999-11-24 2007-03-30 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
ATE344801T1 (en) 1999-12-29 2006-11-15 Immunogen Inc CYTOTOXIC AGENTS CONTAINING DOXORUBICIN AND DAUNORUBICIN AND THEIR THERAPEUTIC USE
DE60143544D1 (en) 2000-12-12 2011-01-05 Medimmune Llc MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2004016753A2 (en) 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP4459810B2 (en) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド FcγRIIB specific antibody and method of use thereof
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2930485C (en) 2003-05-14 2018-04-10 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
BRPI0510674A (en) 2004-07-15 2007-12-26 Xencor Inc optimized fc variants
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CN103554259B (en) 2005-10-12 2016-05-18 莫佛塞斯公司 Specificity is for generation and the qualification of the derivative treatment of the complete people HuCAL GOLD-antibody of people CD38
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
PE20120259A1 (en) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP6049163B2 (en) 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Antibody structural variants for improved therapeutic characteristics
RU2526156C2 (en) 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-immunotherapeutic combination therapy and using it
US20120189618A1 (en) 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
EP2841099A1 (en) * 2012-04-26 2015-03-04 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with bendamustine
JP2015517511A (en) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combined use of CD37 antibody and ICE (ifosfamide, carboplatin, etoposide)
US20130309224A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab
WO2014198330A1 (en) 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with chlorambucil

Also Published As

Publication number Publication date
ME02300B (en) 2016-06-20
AR071242A1 (en) 2010-06-09
EP2178915A2 (en) 2010-04-28
CN101815725A (en) 2010-08-25
US20180186876A1 (en) 2018-07-05
TN2010000068A1 (en) 2011-09-26
PE20120259A1 (en) 2012-04-04
CO6251371A2 (en) 2011-02-21
NZ600022A (en) 2013-11-29
PE20090499A1 (en) 2009-05-18
ECSP109946A (en) 2010-04-30
WO2009019312A3 (en) 2009-04-30
US20100189722A1 (en) 2010-07-29
PE20140196A1 (en) 2014-03-19
SI2178915T1 (en) 2016-01-29
EP2562187A1 (en) 2013-02-27
DK2178915T3 (en) 2015-12-14
TW200916478A (en) 2009-04-16
UA103005C2 (en) 2013-09-10
KR20100054791A (en) 2010-05-25
TWI535733B (en) 2016-06-01
US20140010808A1 (en) 2014-01-09
SG190657A1 (en) 2013-06-28
EP2178915B1 (en) 2015-10-14
JP5238000B2 (en) 2013-07-17
JP2014039541A (en) 2014-03-06
US20110165153A1 (en) 2011-07-07
CN105273086A (en) 2016-01-27
CA2693464C (en) 2017-10-24
CA2693464A1 (en) 2009-02-12
JP5325216B2 (en) 2013-10-23
US20140004110A1 (en) 2014-01-02
JP2011004758A (en) 2011-01-13
EP2562187B1 (en) 2019-03-27
UA105445C2 (en) 2014-05-12
JP2010535483A (en) 2010-11-25
ES2555202T3 (en) 2015-12-29
KR101593403B1 (en) 2016-02-12
ZA200908758B (en) 2010-08-25
TW201512220A (en) 2015-04-01
CL2012002329A1 (en) 2012-12-21
CN103396490A (en) 2013-11-20
RS54359B1 (en) 2016-04-28
WO2009019312A2 (en) 2009-02-12
PH12014501812A1 (en) 2016-10-24
UY31275A1 (en) 2009-03-31
MA32665B1 (en) 2011-10-02
CL2008002349A1 (en) 2009-10-23
IL202645A0 (en) 2011-08-01
PT2178915E (en) 2016-02-04
US9932399B2 (en) 2018-04-03
US9078879B2 (en) 2015-07-14
CN102276724A (en) 2011-12-14
HRP20160009T1 (en) 2016-02-12
HK1220708A1 (en) 2017-05-12
EP2241577A1 (en) 2010-10-20
AR107902A2 (en) 2018-06-28
NZ583713A (en) 2012-07-27
US20160137729A1 (en) 2016-05-19
US20210230271A1 (en) 2021-07-29
ECSP11009946A (en) 2011-09-30
EA027499B1 (en) 2017-08-31
BRPI0823331A2 (en) 2013-07-30
BRPI0815369A2 (en) 2013-03-12
AU2008285590B2 (en) 2014-08-14
EA201000274A1 (en) 2010-10-29
AU2008285590A1 (en) 2009-02-12
PH12014501812B1 (en) 2016-10-24
HUE026221T2 (en) 2016-05-30
MY157555A (en) 2016-06-30
CL2011001592A1 (en) 2012-02-17
PL2178915T3 (en) 2016-03-31
IL202645A (en) 2016-03-31
CY1117101T1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
EA201200994A1 (en) ANTIBODIES TO CD37
LTC2567976I2 (en) Antibodies to CD38 antigen for the treatment of multiple myeloma
MX2010010387A (en) Bcr-complex-specific antibodies and methods of using same.
EA201171374A1 (en) ANTIBODIES AGAINST CD100 AND METHODS OF THEIR APPLICATION
EA201690310A1 (en) HUMAN CD27 ANTIBODIES AND THEIR APPLICATION
EA201391342A1 (en) CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES
EA201390993A1 (en) ANTIBODIES TO CD38
EA201171388A1 (en) HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF BETA AMYLOID PEPTIDE
TW200740844A (en) Novel MAdCAM antibodies
IL228988A (en) Antibody compositions for the treatment of immune related diseases
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
UA118332C2 (en) Cs27l antigen binding proteins
EA201400579A1 (en) ANTIBODIES TO IL-36R
EA201591091A1 (en) Antigen-binding proteins for BCMA
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
EA201201357A1 (en) ANTIBODIES TO CD40
CR10679A (en) NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
EA201270813A1 (en) ANTIBODIES TO N3pGlu BETA AMYLOID PEPTIDE AND THEIR APPLICATION
MY166776A (en) Humanised anti-ctla4 antibodies
EA201300530A1 (en) ANTIBODIES TO IL-23
MX346500B (en) Methods and compositions for neural disease immunotherapy.
EA201401204A1 (en) ANTIBODIES TO IL-23P19
EP2614085A4 (en) Anti-il-1 beta antibodies and methods of use
EA201390467A1 (en) ANTIBODY COMPOSITIONS AND METHODS OF APPLICATION
EA201400447A1 (en) ANTIBODIES TO CD1d